BMS unmoved by rival bid for ImClone Systems
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbwill stand by its $4.4 billion bid forImClone Systems, a day after the offer was rebuffed and a mystery suitor emerged with a competing proposal. BMS also reiterated its claim to the Erbitux (cetuximab) follow-on IMC-11F8, which is a contentious issue for the firms.